Myriad Genetics Inc (MYGN)

Add to Watchlists
Create an Alert
Quickflows
31.15 +0.28  +0.91% NASDAQ Jul 28, 12:53 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All MYGN News

News

View All Events

Events

Date Type Description
08/13/2021 Earnings Results Q4 2021 Earnings Results
08/13/2021 16:30 EST Earnings Calls Q4 2021 Earnings Call
05/04/2021 11:00 EST Earnings Calls Q3 2021 Earnings Call
05/03/2021 Earnings Results Q3 2021 Earnings Results
02/23/2021 Earnings Results Q2 2021 Earnings Results
02/23/2021 16:30 EST Earnings Calls Q2 2021 Earnings Call
12/04/2020 10:00 EST AGM 2020 Annual General Meeting
11/09/2020 Earnings Results Q1 2021 Earnings Results
11/09/2020 17:00 EST Earnings Calls Q1 2021 Earnings Call
08/13/2020 16:30 EST Earnings Calls Q4 2020 Earnings Call
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 575.50M
Total Expenses (TTM) 769.00M
Net Income (TTM) -225.30M

Balance Sheet View Statement

Total Assets (Quarterly) 1.337B
Total Liabilities (Quarterly) 461.70M
Shareholders Equity (Quarterly) 875.20M

Cash Flow Statement View Statement

Cash from Operations (TTM) 59.30M
Cash from Investing (TTM) 58.90M
Cash from Financing (TTM) -51.20M

Ratings & Reports

Advertisement
Edit

Profile

  • Description: Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces myRisk, a 35-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
  • URL: https://www.myriad.com
  • Investor Relations URL: https://myriad.com/investors/news-release/
  • HQ State/Province: Utah
  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Equity Style: Small Cap/Blend
  • Next Earnings Release: Aug. 13, 2021
  • Last Earnings Release: May. 03, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 31.15
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
CCMMX Conestoga Mid Cap Investors 3.01%
PBE Invesco Dynamic Biotech & Genome ETF 2.99%
GNOM Global X Genomics & Biotechnology ETF 2.53%
PSCH Invesco S&P SmallCap Health Care ETF 1.97%
PMJPX PIMCO RAE US Small I-2 1.23%
AZSAX American Beacon Zebra Small Cap Eq A 1.12%
XBI SPDR® S&P Biotech ETF 0.73%

Comparables

Edit
SDC SmileDirectClub Inc
NVST Envista Holdings Corp
HOLX Hologic Inc
BSX Boston Scientific Corp
CNMD Conmed Corp

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.